Blockade of IL-23: What is in the Pipeline?

J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. doi: 10.1093/ecco-jcc/jjab185.


Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.

Keywords: Crohn’s disease; Interleukin 23; anti-IL23 monoclonal antibodies; interleukin 12; ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Crohn Disease* / drug therapy
  • Crohn Disease* / pathology
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Interleukin-23
  • Ustekinumab / therapeutic use


  • Interleukin-23
  • Ustekinumab

Grants and funding